The case for soluble Aβ oligomers as a drug target in Alzheimer's disease

Highlights • Soluble Aβ oligomers are acutely synaptotoxic and contribute to tau pathology. • Confusing terminology and methodologies hamper the science of soluble Aβ oligomers. • There are promising drug discovery targets related to soluble Aβ oligomers. • Translational tools facilitate clinical pr...

Full description

Saved in:
Bibliographic Details
Published inTrends in pharmacological sciences (Regular ed.) Vol. 34; no. 5; pp. 261 - 266
Main Authors Hefti, Franz, Goure, William F, Jerecic, Jasna, Iverson, Kent S, Walicke, Patricia A, Krafft, Grant A
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2013
Subjects
Advanced Basic Science
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Amyloid beta-Peptides - metabolism
Aβ fibrils
Aβ-derived diffusible ligands
Humans
Molecular Targeted Therapy - methods
neurodegeneration
synaptic degeneration
neurodegeneration
Aβ-derived diffusible ligands
synaptic degeneration
Aβ fibrils
Online AccessGet full text

Cover

More Information
Summary:Highlights • Soluble Aβ oligomers are acutely synaptotoxic and contribute to tau pathology. • Confusing terminology and methodologies hamper the science of soluble Aβ oligomers. • There are promising drug discovery targets related to soluble Aβ oligomers. • Translational tools facilitate clinical proof of concept in short trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2013.03.002